We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Confocal Fluorescence Microscopy Used for Rapid Tissue Evaluation

By LabMedica International staff writers
Posted on 16 Apr 2018
Print article
Image: The Vivascope 2500 confocal scanning microscopic view of lymph node metastases from thyroid carcinoma are papillary structures made up of scanty bright spots floating in a dark background (left) (Photo courtesy of IRCSS Santa Maria Nuova Hospital).
Image: The Vivascope 2500 confocal scanning microscopic view of lymph node metastases from thyroid carcinoma are papillary structures made up of scanty bright spots floating in a dark background (left) (Photo courtesy of IRCSS Santa Maria Nuova Hospital).
Optical imaging techniques are currently available for imaging tissues without the need for any type of extensive tissue preparation. There are several applications for their potential use in surgical pathology practice.

Unlike in vivo optical imaging, ex vivo optical imaging is not yet routinely used in clinical practice, although several optical imaging modalities are available for ex vivo tissue examination. These techniques include full-field optical coherence tomography, confocal fluorescence microscopy (CFM), and multiphoton microscopy.

Pathology specialists at the University of Texas MD Anderson Cancer Center (Houston, TX, USA) evaluated the feasibility of using a confocal fluorescence microscopy (CFM) platform for ex vivo examination of tissues obtained from surgical resections of breast, lung, kidney, and liver. The team collected fragments of fresh tissue from normal as well as areas of tumor from a total of 55 surgical resections that were performed for malignant tumors of the breast, liver, lung, and kidney soon after completion of immediate intraoperative assessment of the surgical specimen.

The tissue fragments (0.5–1.0 cm) were immersed in 0.6 mM acridine orange for six seconds and imaged using a CFM platform at a 488-nm wavelength. The CFM images of the specimen were obtained using a confocal scanning microscope designed specifically for ex vivo imaging of fresh biologic tissue specimens. The imaged tissues were subsequently fixed in formalin and processed routinely to generate hematoxylin-eosin–stained tissue sections. Mosaics of the grayscale CFM images were studied at different magnifications for recognition of the tissue and were compared with conventional histopathologic examination of hematoxylin-eosin tissue sections.

The scientists imaged 55 tissue fragments obtained from 16 breast (29%), 18 lung (33%), 14 kidney (25%), and seven liver (13%) surgical excision specimens. Acridine orange labeled the nuclei, creating the contrast between nucleus and cytoplasm and thereby recapitulating the tissue architecture. They obtained CFM images of good quality within 5 to 10 minutes that allowed recognition of the cytomorphologic details for categorization of the imaged tissue and were similar to histologic examination of hematoxylin-eosin tissue sections.

The authors concluded that the relative ease and speed of grayscale image acquisition together with the quality of images that were obtained with the CFM platform used in their study suggest that this technique has promise for use in surgical pathology practice. The CFM images are similar to H&E images and the use of this CFM technique for possible applications in surgical pathology, such as rapid evaluation of specimen adequacy of core needle biopsy at the time of procurement, margin evaluation of surgical resection specimens, and quality assurance of the tissues for biobanking, needs serious consideration. The study was published in the March 2018 issue of the journal Archives Of Pathology & Laboratory Medicine.

Related Links:
University of Texas MD Anderson Cancer Center

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Karius Focus BAL is designed to quickly identify the etiology of lung infections and improve diagnostic yield over standard of care testing (Photo courtesy of Karius)

Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections

Bronchoalveolar lavage (BAL) is a commonly used procedure for diagnosing lung infections, especially in immunocompromised patients. However, standard tests often fail to pinpoint the exact pathogen, leading... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.